Laquinimod-d5

Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research[1].

Product Specifications

CAS Number

[1214267-09-0]

Product Name Alternative

ABR-215062-d5

UNSPSC

12352005

Target

Apoptosis; Isotope-Labeled Compounds; NF-κB

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; NF-κB; Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Purity

98.25

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

[2H]C1=C([2H])C([2H])=C(N(C(C2=C(O)C3=C(N(C)C2=O)C=CC=C3Cl)=O)CC)C([2H])=C1[2H]

Molecular Formula

C19H12D5ClN2O3

Molecular Weight

361.83

References & Citations

[1]Varrin-Doyer M, et al. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp Neurol. 2014 Dec;262 Pt A:66-71.